Jump to content
RemedySpot.com

Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Oct 23. [Epub ahead of print]

Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.

Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, J, Dore GJ.

National Centre in HIV Epidemiology and Clinical Research, The University of New

South Wales, Sydney, Australia; New South Wales Department of Health, Sydney,

Australia.

Abstract

BACKGROUND & AIMS: Chronic hepatitis B (HBV) or C (HCV) virus infection has been

associated with increased risk of death, particularly from liver- and

drug-related causes. We examined specific causes of death among a

population-based cohort of people infected with HBV or HCV to identify areas of

excess risk and examine trends in mortality.

METHODS: HBV and HCV cases notified to the New South Wales (NSW) Health

Department between 1992 and 2006 were linked to cause of death data and HIV/AIDS

notifications. Mortality rates and standardised mortality ratios (SMRs) were

calculated using person time methodology, with NSW population rates used as a

comparison.

RESULTS: The study cohort comprised 42,480 individuals with HBV mono-infection

and 82,034 with HCV mono-infection. HIV co-infection increased the overall

mortality rate three to ten-fold compared to mono-infected groups. Liver-related

deaths were associated with high excess risk of mortality in both HBV and HCV

groups (SMR 10.0, 95%CI 9.0-11.1; 15.8, 95%CI 14.8-16.8). Drug-related deaths

among the HCV group also represented an elevated excess risk (SMR 15.4, 95%CI

14.5-16.3). Rates of hepatocellular carcinoma (HCC)-related death remained

steady in both groups. A decrease in non-HCC liver-related deaths was seen in

the HBV group between 1997 and 2006, but not in the HCV group. After a sharp

decrease between 1999 and 2002, drug-related mortality rates in the HCV group

have been stable.

CONCLUSIONS: Improvements in HBV treatment and uptake have most likely reduced

non-HCC liver-related mortality. Encouragingly, HCV drug-related mortality

remained low compared to pre-2002 levels, likely due to changes in opiate

supply, and maintenance or improvement in harm reduction strategies.

. Published by Elsevier B.V.

PMID: 21145812 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Oct 23. [Epub ahead of print]

Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.

Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, J, Dore GJ.

National Centre in HIV Epidemiology and Clinical Research, The University of New

South Wales, Sydney, Australia; New South Wales Department of Health, Sydney,

Australia.

Abstract

BACKGROUND & AIMS: Chronic hepatitis B (HBV) or C (HCV) virus infection has been

associated with increased risk of death, particularly from liver- and

drug-related causes. We examined specific causes of death among a

population-based cohort of people infected with HBV or HCV to identify areas of

excess risk and examine trends in mortality.

METHODS: HBV and HCV cases notified to the New South Wales (NSW) Health

Department between 1992 and 2006 were linked to cause of death data and HIV/AIDS

notifications. Mortality rates and standardised mortality ratios (SMRs) were

calculated using person time methodology, with NSW population rates used as a

comparison.

RESULTS: The study cohort comprised 42,480 individuals with HBV mono-infection

and 82,034 with HCV mono-infection. HIV co-infection increased the overall

mortality rate three to ten-fold compared to mono-infected groups. Liver-related

deaths were associated with high excess risk of mortality in both HBV and HCV

groups (SMR 10.0, 95%CI 9.0-11.1; 15.8, 95%CI 14.8-16.8). Drug-related deaths

among the HCV group also represented an elevated excess risk (SMR 15.4, 95%CI

14.5-16.3). Rates of hepatocellular carcinoma (HCC)-related death remained

steady in both groups. A decrease in non-HCC liver-related deaths was seen in

the HBV group between 1997 and 2006, but not in the HCV group. After a sharp

decrease between 1999 and 2002, drug-related mortality rates in the HCV group

have been stable.

CONCLUSIONS: Improvements in HBV treatment and uptake have most likely reduced

non-HCC liver-related mortality. Encouragingly, HCV drug-related mortality

remained low compared to pre-2002 levels, likely due to changes in opiate

supply, and maintenance or improvement in harm reduction strategies.

. Published by Elsevier B.V.

PMID: 21145812 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Oct 23. [Epub ahead of print]

Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.

Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, J, Dore GJ.

National Centre in HIV Epidemiology and Clinical Research, The University of New

South Wales, Sydney, Australia; New South Wales Department of Health, Sydney,

Australia.

Abstract

BACKGROUND & AIMS: Chronic hepatitis B (HBV) or C (HCV) virus infection has been

associated with increased risk of death, particularly from liver- and

drug-related causes. We examined specific causes of death among a

population-based cohort of people infected with HBV or HCV to identify areas of

excess risk and examine trends in mortality.

METHODS: HBV and HCV cases notified to the New South Wales (NSW) Health

Department between 1992 and 2006 were linked to cause of death data and HIV/AIDS

notifications. Mortality rates and standardised mortality ratios (SMRs) were

calculated using person time methodology, with NSW population rates used as a

comparison.

RESULTS: The study cohort comprised 42,480 individuals with HBV mono-infection

and 82,034 with HCV mono-infection. HIV co-infection increased the overall

mortality rate three to ten-fold compared to mono-infected groups. Liver-related

deaths were associated with high excess risk of mortality in both HBV and HCV

groups (SMR 10.0, 95%CI 9.0-11.1; 15.8, 95%CI 14.8-16.8). Drug-related deaths

among the HCV group also represented an elevated excess risk (SMR 15.4, 95%CI

14.5-16.3). Rates of hepatocellular carcinoma (HCC)-related death remained

steady in both groups. A decrease in non-HCC liver-related deaths was seen in

the HBV group between 1997 and 2006, but not in the HCV group. After a sharp

decrease between 1999 and 2002, drug-related mortality rates in the HCV group

have been stable.

CONCLUSIONS: Improvements in HBV treatment and uptake have most likely reduced

non-HCC liver-related mortality. Encouragingly, HCV drug-related mortality

remained low compared to pre-2002 levels, likely due to changes in opiate

supply, and maintenance or improvement in harm reduction strategies.

. Published by Elsevier B.V.

PMID: 21145812 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Oct 23. [Epub ahead of print]

Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.

Walter SR, Thein HH, Amin J, Gidding HF, Ward K, Law MG, J, Dore GJ.

National Centre in HIV Epidemiology and Clinical Research, The University of New

South Wales, Sydney, Australia; New South Wales Department of Health, Sydney,

Australia.

Abstract

BACKGROUND & AIMS: Chronic hepatitis B (HBV) or C (HCV) virus infection has been

associated with increased risk of death, particularly from liver- and

drug-related causes. We examined specific causes of death among a

population-based cohort of people infected with HBV or HCV to identify areas of

excess risk and examine trends in mortality.

METHODS: HBV and HCV cases notified to the New South Wales (NSW) Health

Department between 1992 and 2006 were linked to cause of death data and HIV/AIDS

notifications. Mortality rates and standardised mortality ratios (SMRs) were

calculated using person time methodology, with NSW population rates used as a

comparison.

RESULTS: The study cohort comprised 42,480 individuals with HBV mono-infection

and 82,034 with HCV mono-infection. HIV co-infection increased the overall

mortality rate three to ten-fold compared to mono-infected groups. Liver-related

deaths were associated with high excess risk of mortality in both HBV and HCV

groups (SMR 10.0, 95%CI 9.0-11.1; 15.8, 95%CI 14.8-16.8). Drug-related deaths

among the HCV group also represented an elevated excess risk (SMR 15.4, 95%CI

14.5-16.3). Rates of hepatocellular carcinoma (HCC)-related death remained

steady in both groups. A decrease in non-HCC liver-related deaths was seen in

the HBV group between 1997 and 2006, but not in the HCV group. After a sharp

decrease between 1999 and 2002, drug-related mortality rates in the HCV group

have been stable.

CONCLUSIONS: Improvements in HBV treatment and uptake have most likely reduced

non-HCC liver-related mortality. Encouragingly, HCV drug-related mortality

remained low compared to pre-2002 levels, likely due to changes in opiate

supply, and maintenance or improvement in harm reduction strategies.

. Published by Elsevier B.V.

PMID: 21145812 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...